Comprehensive Human Urine Standards for Comparability and Standardization in Clinical Proteome Analysis

Overview

Journal Proteomics Clin Appl

Specialty Biochemistry

Date 2010 Dec 8

PMID 21137064

Citations 60

Authors

Harald Mischak

Walter Kolch

Michalis Aivaliotis

David Bouyssie

Magali Court

Hassan Dihazi

Gry H Dihazi

Julia Franke

Jerome Garin

Anne Gonzalez de Peredo

Alexander Iphofer

Lothar Jansch

Chrystelle Lacroix

Manousos Makridakis

Christophe Masselon

Jochen Metzger

Bernard Monsarrat

Michal Mrug

Martin Norling

Jan Novak

Andreas Pich

Andrew Pitt

Erik Bongcam-Rudloff

Justyna Siwy

Hitoshi Suzuki

Visith Thongboonkerd

Li-Shun Wang

Jerome Zoidakis

Petra Zurbig

Joost P Schanstra

Antonia Vlahou

Affiliations

Soon will be listed here.

Abstract

Purpose: Urine proteomics is emerging as a powerful tool for biomarker discovery. The purpose of this study is the development of a well-characterized "real life" sample that can be used as reference standard in urine clinical proteomics studies.

Experimental Design: We report on the generation of male and female urine samples that are extensively characterized by different platforms and methods (CE-MS, LC-MS, LC-MS/MS, 1-D gel analysis in combination with nano-LC MS/MS (using LTQ-FT ultra), and 2-DE-MS) for their proteome and peptidome. In several cases analysis involved a definition of the actual biochemical entities, i.e. proteins/peptides associated with molecular mass and detected PTMs and the relative abundance of these compounds.

Results: The combination of different technologies allowed coverage of a wide mass range revealing the advantages and complementarities of the different technologies. Application of these samples in "inter-laboratory" and "inter-platform" data comparison is also demonstrated.

Conclusions And Clinical Relevance: These well-characterized urine samples are freely available upon request to enable data comparison especially in the context of biomarker discovery and validation studies. It is also expected that they will provide the basis for the comprehensive characterization of the urinary proteome.

Citing Articles

Development and Challenges of Pre-Heart Failure with Preserved Ejection Fraction.

Dong G Rev Cardiovasc Med. 2024; 24(9):274.

PMID: 39076392 PMC: 11270127. DOI: 10.31083/j.rcm2409274.

OSTEO18, a novel urinary proteomic signature, associated with osteoporosis in heart transplant recipients.

Yu Y, Huang Q, An D, Raad J, Martens D, Latosinska A Heliyon. 2024; 10(2):e24867.

PMID: 38312576 PMC: 10835361. DOI: 10.1016/j.heliyon.2024.e24867.

Urine Peptidome Analysis Identifies Common and Stage-Specific Markers in Early Versus Advanced CKD.

Hobson S, Mavrogeorgis E, He T, Siwy J, Ebert T, Kublickiene K Proteomes. 2023; 11(3).

PMID: 37755704 PMC: 10534506. DOI: 10.3390/proteomes11030025.

Urinary peptides provide information about the risk of mortality across a spectrum of diseases and scenarios.

Keller F, Beige J, Siwy J, Mebazaa A, An D, Mischak H J Transl Med. 2023; 21(1):663.

PMID: 37741989 PMC: 10518109. DOI: 10.1186/s12967-023-04508-6.

Urinary peptidomic liquid biopsy for non-invasive differential diagnosis of chronic kidney disease.

Mavrogeorgis E, He T, Mischak H, Latosinska A, Vlahou A, Schanstra J Nephrol Dial Transplant. 2023; 39(3):453-462.

PMID: 37697716 PMC: 10899775. DOI: 10.1093/ndt/gfad200.

References

Pang J, Ginanni N, Dongre A, Hefta S, Opitek G . Biomarker discovery in urine by proteomics. J Proteome Res. 2003; 1(2):161-9. DOI: 10.1021/pr015518w. View

Havanapan P, Thongboonkerd V . Are protease inhibitors required for gel-based proteomics of kidney and urine?. J Proteome Res. 2009; 8(6):3109-17. DOI: 10.1021/pr900015q. View

Theodorescu D, Wittke S, Ross M, Walden M, Conaway M, Just I . Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol. 2006; 7(3):230-40. DOI: 10.1016/S1470-2045(06)70584-8. View

Davis M, Spahr C, McGinley M, Robinson J, Bures E, Beierle J . Towards defining the urinary proteome using liquid chromatography-tandem mass spectrometry. II. Limitations of complex mixture analyses. Proteomics. 2001; 1(1):108-17. DOI: 10.1002/1615-9861(200101)1:1<108::AID-PROT108>3.0.CO;2-5. View

Schaub S, Wilkins J, Weiler T, Sangster K, Rush D, Nickerson P . Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int. 2003; 65(1):323-32. DOI: 10.1111/j.1523-1755.2004.00352.x. View

Suzuki H, Moldoveanu Z, Hall S, Brown R, Vu H, Novak L . IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest. 2008; 118(2):629-39. PMC: 2157566. DOI: 10.1172/JCI33189. View

Oh J, Pyo J, Jo E, Hwang S, Kang S, Jung J . Establishment of a near-standard two-dimensional human urine proteomic map. Proteomics. 2004; 4(11):3485-97. DOI: 10.1002/pmic.200401018. View

Pisitkun T, Johnstone R, Knepper M . Discovery of urinary biomarkers. Mol Cell Proteomics. 2006; 5(10):1760-71. DOI: 10.1074/mcp.R600004-MCP200. View

Thongboonkerd V, McLeish K, Arthur J, Klein J . Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int. 2002; 62(4):1461-9. DOI: 10.1111/j.1523-1755.2002.kid565.x. View

10.

Thongboonkerd V, Mungdee S, Chiangjong W . Should urine pH be adjusted prior to gel-based proteome analysis?. J Proteome Res. 2009; 8(6):3206-11. DOI: 10.1021/pr900127x. View

11.

Decramer S, Gonzalez de Peredo A, Breuil B, Mischak H, Monsarrat B, Bascands J . Urine in clinical proteomics. Mol Cell Proteomics. 2008; 7(10):1850-62. DOI: 10.1074/mcp.R800001-MCP200. View

12.

Gonzales P, Pisitkun T, Hoffert J, Tchapyjnikov D, Star R, Kleta R . Large-scale proteomics and phosphoproteomics of urinary exosomes. J Am Soc Nephrol. 2008; 20(2):363-79. PMC: 2637050. DOI: 10.1681/ASN.2008040406. View

13.

Kistler A, Mischak H, Poster D, Dakna M, Wuthrich R, Serra A . Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney Int. 2009; 76(1):89-96. DOI: 10.1038/ki.2009.93. View

14.

Zerefos P, Vougas K, Dimitraki P, Kossida S, Petrolekas A, Stravodimos K . Characterization of the human urine proteome by preparative electrophoresis in combination with 2-DE. Proteomics. 2006; 6(15):4346-55. DOI: 10.1002/pmic.200500671. View

15.

Chevallet M, Diemer H, Van Dorssealer A, Villiers C, Rabilloud T . Toward a better analysis of secreted proteins: the example of the myeloid cells secretome. Proteomics. 2007; 7(11):1757-70. PMC: 2386146. DOI: 10.1002/pmic.200601024. View

16.

Rossing K, Mischak H, Dakna M, Zurbig P, Novak J, Julian B . Urinary proteomics in diabetes and CKD. J Am Soc Nephrol. 2008; 19(7):1283-90. PMC: 2440301. DOI: 10.1681/ASN.2007091025. View

17.

Jantos-Siwy J, Schiffer E, Brand K, Schumann G, Rossing K, Delles C . Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res. 2008; 8(1):268-81. DOI: 10.1021/pr800401m. View

18.

Haubitz M, Good D, Woywodt A, Haller H, Rupprecht H, Theodorescu D . Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis. Mol Cell Proteomics. 2009; 8(10):2296-307. PMC: 2758757. DOI: 10.1074/mcp.M800529-MCP200. View

19.

Snell-Bergeon J, Maahs D, Ogden L, Kinney G, Hokanson J, Schiffer E . Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease. Diabetes Technol Ther. 2009; 11(1):1-9. PMC: 2939844. DOI: 10.1089/dia.2008.0040. View

20.

Zurbig P, Decramer S, Dakna M, Jantos J, Good D, Coon J . The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease. Proteomics. 2009; 9(8):2108-17. PMC: 2768386. DOI: 10.1002/pmic.200800560. View